<article id="febrile_neutropenia_p" class="slide" data-ag-slide-name="Febrile Neutropenia (P)">
    <div class="basic">
      <div id="fb_main_image_p" class="image_style"></div>
      <div class="main_content_style" id="fb_right_panel">
         <p data-ag-editable="Febrile Neutropenia (P) Main Copy">Febrile neutropenia is defined as an absolute neutrophil count of &lt;0.5 x 10<sup>9</sup>/L or &lt;1.0 x 10<sup>9</sup>/L predicted to fall below 0.5 x 10<sup>9</sup>/L within 48 hours, with fever or clinical signs of sepsis<sup>1</sup></p>
      </div>
      <div class="main_content_style" id="fb_bottom_panel">
         <p data-ag-editable="Febrile Neutropenia (P) Bottom Copy">As early as the first cycle, cancer patients are at risk of hospitalisation and mortality due to FN<sup>2-5</sup></p>
      </div>
    </div>
    <!-- Reference Information Starts -->
    <div class="lightbox_data" id="febrile_neutropenia_p_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Febrile Neutropenia (P) References Title">References:</strong></p>
          <div data-ag-editable="Febrile Neutropenia (P) References List">
             <ol>
                <li>Aapro MS <em>et al</em>. 2010 update of EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8–32</li>
                <li>Von Minckwitz G <em>et al</em>. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis. Eur J Cancer 2009;45:608–617</li>
                <li>Pettengell R <em>et al</em>. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalisations among patients with diffuse large B-cell lymphoma Supp Care Cancer 2012;20(3):647-52</li>
                <li>Aarts M <em>et al</em>. Primary G-Csf Prophylaxis During The First Two Cycles Only Or Throughout All Chemotherapy Cycles In Breast Cancer Patients At Risk Of Febrile Neutropenia: First Results From A Phase III Trial Of The Dutch Breast Cancer Trialists Group (Boog). Supp Care Cancer 2010;18(Suppl 3):S115-116</li>
                <li>Kuderer N <em>et al</em>. Impact of Primary Prophylaxis With Granulocyte Colony- Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review. J Clin Oncol. 2007; 25(21):3158-3167</li>
             </ol>
          </div>
       </div>
    </div>
    <!-- Reference Information Ends -->
</article>